.jpg)
.jpg)
.jpg)
Recommended
December 09, 2024
2024 Recap: Top 10 Breakthroughs in Ophthalmology Research
2024 has been a landmark year for breakthroughs in ophthalmology research, showcasing transformative advancements that are shaping the future of eye care.
Breaking News
Adverse Effects Identified Following Faricimab Treatment for Eye Conditions
Oct 15, 2024
Researchers from the University Hospital Zurich have reported cases of sterile intraocular inflammation, including severe retinal vasculitis, associated with faricimab injections.
Eye Drop Company Faces FDA Scrutiny Again Over Unapproved Products
Sep 19, 2024
The FDA has issued a warning letter to the Regenerative Processing Plant, manufacturer of Regener-Eyes Pro and Lite eye drops, for marketing unapproved products claiming to treat dry eyes.
Maestro®: The Sinusoidal IOL
Sep 18, 2024
VSY Biotechnology introduced the Maestro® Sinusoidal IOL at ESCRS 2024, featuring SVT. This innovative trifocal lens enhances visual acuity, contrast sensitivity, and light transmission, offering a cutting-edge solution for presbyopia management.
.jpg)
Industry News
Nonsteroidal Immunomodulator VVN461 Meets Endpoints in Post-Cataract Surgery Inflammation Trial
Dec 10, 2024
VivaVision Biotech has announced promising phase 2 clinical trial results for VVN461, a nonsteroidal dual Janus kinase 1/tyrosine kinase 2 immunomodulator.
OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiative
Dec 09, 2024
The OneSight EssilorLuxottica Foundation has entered a strategic partnership with the World Health Organization (WHO) as a global collaborator in the SPECS 2030 initiative.
Cambium Bio Secures Funding to Advance Dry Eye Disease Treatment
Dec 06, 2024
Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round.
Ophthalmic Research News
Empagliflozin Linked to Reduced Progression of Diabetic Retinopathy
Dec 10, 2024
A study led by Brigham and Women's Hospital has revealed that empagliflozin a sodium-glucose cotransporter-2 inhibitor may significantly reduce the risk of diabetic retinopathy progression in patients with nonproliferative diabetic retinopathy.
UC Irvine Scientists Identify DNA Damage as a Key Factor in AMD
Dec 09, 2024
A groundbreaking study led by researchers at the University of California, Irvine, has identified accumulated DNA damage in the retina as a critical factor in the development of age-related macular degeneration (AMD).
New Research Reveals Exceptional Sensitivity of the Human Visual System
Dec 06, 2024
A groundbreaking study by researchers at the University of Helsinki has uncovered the neural mechanisms behind the extraordinary sensitivity of human vision in near-darkness.
Ophthalmic Blog
2024 Recap: Top 10 Breakthroughs in Ophthalmology Research
Dec 09, 2024
2024 has been a landmark year for breakthroughs in ophthalmology research, showcasing transformative advancements that are shaping the future of eye care.
2024 Recap: Top 10 Company Acquisitions in the Ophthalmic Industry
Dec 04, 2024
In 2024, the ophthalmic industry experienced a transformative year driven by strategic company acquisitions, paving the way for groundbreaking advancements and innovative collaborations.
Global Myopia Rates in Children and Teens Expected to Surpass 740 Million by 2050
Oct 01, 2024
A new analysis published in the British Journal of Ophthalmology reveals that nearly one in three children and teens worldwide is expected to be affected by myopia by 2050, translating to over 740 million cases.
Ophthalmology Breaking News Subscribe